Navigation Links
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
Date:10/7/2010

rough its two subsidiaries – Biospherics Incorporated and Spherix Consulting, Inc.  Biospherics recently completed a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes.  Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.

Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchan
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Announces Second Quarter 2010 Financial Results
2. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
3. Spherix Announces Results of Annual Shareholders Meeting
4. Spherix Incorporated Announces Annual Shareholders Meeting Date
5. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
6. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Spherix Reports Second Quarter 2009 Earnings
8. Spherix Announces Termination of Arla License Agreement
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Regains Full NASDAQ Compliance
11. Spherix to Exhibit at the BIO 2009 International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Conferee ... for Topics for Conferee Networking. These two-hour sessions provide ... to meet and resolve problems, discuss new techniques, or ... deadline to submit a topic for consideration is August ... pittcon.org . The Conferee Networking committee will review the ...
(Date:7/25/2014)... AVIV, Israel , July 25, 2014  Galmed ... clinical-stage biopharmaceutical company focused on the development and commercialization ... liver diseases and cholesterol gallstones, today announced financial results ... First Half 2014 Financial Summary: , Reported cash ... 2014, compared with $137,000 at December 31, 2013.  ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
Breaking Biology Technology:Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... INTRODUCTION , ... encoded bacterial enzymes which hydrolyze β -lactam antibiotics. The majority of ... One successful approach to combating the serine active site β -lactamases ... in combination with a β -lactam antibiotic 4 . , There ...
... , Evelyn McGown and Michael Su , ... fluorogenic oligonucleotide probes developed by Kramerand associates to detect ... They are single-stranded oligonucleotides that exist in a ... which bind together to form a stem. Thestrained loop ...
... , Anne T. Ferguson, Ph.D., ... , , INTRODUCTION , This ... XS from Molecular Devices to study the performance of the LIVE/DEAD ... two fluorescent dyes, calcein AM (cal AM) and ethidium homodimer (EthD-1), ...
Cached Biology Technology:A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 2A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 3A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 4A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 5A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20) 6Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 2Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 3Measurement of Molecular Beacons in the SpectraMax Gemini Spectrofluorometer (MaxLine Application Note #36) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 2LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 3LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 4LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43) 5
(Date:7/25/2014)... associate professor of biomedical engineering at the University ... tissue engineering and artificial organ development., "Introduction to ... guide to entering into the field of artificial ... of biomedical engineering at UH, served as a ... while there are other published books on the ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2New hope for powdery mildew resistant barley 2
... effort to make data storage more cost-effective, a group of ... Karlsruhe Institute of Technology in Germany have created a DNA-based ... (UV) light to make it possible to encode information. The ... Applied Physics Letters , consists of a thin film of ...
... Athens, Ga. The knowledge that bacteria possess adaptable immune ... invaders is relatively new to science, and researchers across the ... to apply that knowledge in industry and medicine. ... how to harness this bacterial immune system to selectively target ...
... Ore. - Newly published research by scientists at Oregon ... how early embryonic stem cells develop and take part ... took place at OHSU,s Oregon National Primate Research Center, ... chimeric monkeys -- monkeys developed from stem cells taken ...
Cached Biology News:UGA scientists 'hijack' bacterial immune system 2UGA scientists 'hijack' bacterial immune system 3OHSU research produces the world's first primate chimeric offspring 2
activating transcription factor 4 (tax-responsive enhancer element B67),...
Request Info...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: